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Abstract
In recent years improved cure rates have been achieved for testicular cancer. A better understanding of the biology of
subtypes of testicular cancer and the introduction of surgical intervention has contributed greatly to how we currently
approach a young man with testicular cancer. We describe here experience at our institution of the treatment, results and
prognostic factors for testicular cancer metastases to the liver. Careful diagnostic work-up and planning of the therapy are
required, in cooperation with an experienced team.
Background
Testicular cancer has often been described as ‘the
model of a curable cancer’. This was not always the
case, as prior to the mid-1970s; treatment curedB/5%
of patients. Given that this was and remains the most
common cancer in young men (aged 1535), there
was a great impetus to find better methods of
treatment. For two decades, this centered on che-
motherapeutic regimens using multiple drugs with
non-overlapping toxicity profiles [1]. By 1984, the
cure rate for testicular cancer was /80% and experi-
mental protocols began to focus on the refractory
cases or ‘poor risk’ patients. However, chemotherapy
alone has not been the only intervention to contribute
to this dramatic improvement. A better understanding
of the biology of subtypes of testicular cancer and the
introduction of surgical intervention has contributed
greatly to how we currently approach a young man
with testicular cancer [24].
Experience and results
Our institution has been a proponent of aggressive
medical and surgical management for testicular can-
cer, including resection of multiple foci of disease that
is not eradicated by chemotherapy alone [1]. Hepatic
resection for other cancers, like colorectal carcinoma,
has been shown to improve survival in selected
patients and prognostic variables have been described
to predict outcome in these patients [57]. Hepatic
resection as part of a primary debulking or interval
debulking for metastatic ovarian cancer has also
shown a survival benefit in patients that can be
rendered free of all (or nearly all) measurable disease
[8,9]. Although the pattern of spread for testicular
cancer is usually lymphatically to retroperitoneal
lymph nodes and hematogenously to the pulmonary
parenchyma, it may also spread to the liver. We have
had encouraging results with hepatic resection of
metastatic testicular carcinoma. We published our
first series of patients in 1990, having treated 28
patients with disseminated germ cell carcinoma [10].
The lessons learned from this series include: (1) it
can be done safely, without a significant increase in
morbidity and mortality (we observed no deaths and
28% of patients experienced complications), and (2)
survival was predicted by histopathologic character-
istics of the specimen(s) as we would have predicted
based on extrahepatic metastatectomy series.
Our most recent series of 57 patients treated with
hepatic resection for metastatic testicular cancer
highlights our current treatment algorithm and prog-
nostic indicators [11]. Patients receive at least three
cycles of cisplatin-based chemotherapy, after which
tumor marker levels of human chorionic gonadotro-
pin (B-HCG) and alpha-fetoprotein (AFP) are reas-
sessed. Patients are then stratified into three groups:
(a) those with normalization of their serum markers
and no radiographic evidence of disease, (b) patients
with normalization of serum markers with evidence of
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persistent disease on follow-up imaging, and (3)
patients with elevated serum markers and persistent
disease. The first group is followed closely with serum
marker analysis and imaging for evidence of relapse.
Patients with normalized serum markers and radio-
graphic evidence of disease are candidates for surgical
resection. Patients with elevated serum markers are
usually treated with salvage chemotherapy. These
latter two groups make up the cohort of 57 patients
who underwent a total of 60 hepatic resections at
our institution. Concomitant procedures were per-
formed in 87% of patients and included: (a) retro-
peritoneal lymph node dissections (RPLND, n/37),
(b) RPLND with pulmonary or mediastinal resection
(n/10), (c) nephrectomy (n/5), IVC resection (n/
3), and orchiectomy (n/1). Postoperatively, hepatic
specimens were evaluated and patients were again
stratified into groups based on histopathologic char-
acteristics: group 1 had no evidence of cancer (i.e.
necrosis or fibrosis) in the resected specimen(s),
group 2 had histopathologic evidence of teratoma,
group 3a had persistent germ cell cancer in the face of
normal preoperative serum markers, and group 3b
had active disease and persistent elevation of serum
markers preoperatively. With a median followup of
47.1 months, eight of nine (89%) patients in group 1
were alive with no evidence of disease at last follow-
up. With a median follow-up of 56.9 months, 21 of
29 (72%) patients in group 2 had no evidence of
disease. Despite the presence of persistent cancer in
the resected hepatic metastases, 6 of 14 patients in
group 3a and 2 of 5 patients in group 3b remain alive
and disease-free, with a median follow-up period of
20.4 months. Overall, 37 of 57 patients continue to
remain disease-free. Favorable prognostic variables
included: (1) no histopathologic evidence of cancer
within the liver specimen and (2) normalization of
preoperative serum markers in ‘poor risk’ patients
with histopathologic evidence of active disease in their
resected specimen(s).
The vast majority of patients diagnosed with meta-
static testicular cancer are cured with chemotherapy
alone. Our ability to establish treatment expectations
has a lot to do with the development of staging
systems that effectively discriminate ‘good risk’ from
‘poor risk’ disease. Patients with hepatic metastases
fall into the ‘advanced’ or ‘poor risk’ category in the
current International Staging System [12]. This group
also includes other nonpulmonary visceral metastases
and markedly elevated serum b-HCG and/or AFP.
These patients have a 4060% cure rate with stan-
dard therapy [12]. High dose chemotherapy with
peripheral stem cells has been used effectively as
salvage therapy in these high risk patients with
improvement in survival [1].
Conclusion
Our success in the treatment of metastatic germ cell
tumors is achieved by multidisciplinary efforts. In
some cases complete excision requires multivisceral
radical resections as a last attempt to cure patients
who have exhausted all other therapeutic options.
Complete surgical resection of all measurable disease
is the gold standard and correlates with improvement
in both relapse-free and overall survival after hepa-
tectomy with actuarial survival rates of 78% at 3 years
in other tumor types [13]. This requires careful
diagnostic work-up and planning of the procedure in
cooperation with an experienced team.
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